EQRx is uniquely positioned to revolutionize how medicines are brought to patients through innovation and strategic collaboration across global healthcare systems—it’s an opportunity to make a real impact.


Michael Doherty has more than two decades of expertise in product development and global regulatory strategy.

Previously, Michael was head of product development and R&D for Foundation Medicine, where he led development of the FoundationOne®CDx assay, the first FDA-approved broad sequencing panel for oncology. Michael also spearheaded the parallel review process to accelerate access to this test.

Before that, Michael spent 15 years at Roche leading the strategic innovation team, which focused on ensuring future sustainability for drug development. He also delivered a world-leading oncology portfolio as the global head of regulatory affairs.

View All